{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["de Blanck SR"],"funding":["Novo Nordisk Fonden"],"pagination":["24-28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6154396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0-38?months). Marker volume reduction was seen until 9?months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found."],"journal":["Clinical and translational radiation oncology"],"pubmed_title":["Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer."],"pmcid":["PMC6154396"],"funding_grant_id":["NNF15OC0016796"],"pubmed_authors":["Larsen KR","Jolck RI","Persson GF","Josipovic M","Andresen TL","Aznar MC","de Blanck SR","Rydhog JS","Specht L","Clementsen PF","Af Rosenschold PM"],"additional_accession":[]},"is_claimable":false,"name":"Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer.","description":"Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0-38?months). Marker volume reduction was seen until 9?months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Nov","modification":"2021-02-19T08:36:44Z","creation":"2019-03-26T23:57:39Z"},"accession":"S-EPMC6154396","cross_references":{"pubmed":["30258990"],"doi":["10.1016/j.ctro.2018.07.004"]}}